Atea Pharmaceuticals (AVIR)
(Real Time Quote from BATS)
$3.51 USD
+0.01 (0.29%)
Updated Sep 25, 2024 10:30 AM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Atea Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 578 | 647 | 764 | 856 | 22 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 14 | 8 | 8 | 0 |
Total Current Assets | 590 | 661 | 772 | 863 | 22 |
Net Property & Equipment | 1 | 2 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 2 | 0 | 0 | 0 |
Total Assets | 595 | 667 | 773 | 864 | 22 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 5 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 27 | 15 | 52 | 14 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 301 | 0 |
Total Current Liabilities | 32 | 18 | 57 | 316 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 5 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 6 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 40 | 26 | 63 | 316 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 69 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 751 | 701 | 654 | 613 | 5 |
Retained Earnings | -196 | -60 | 56 | -65 | -54 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 555 | 641 | 710 | 548 | 20 |
Total Liabilities & Shareholder's Equity | 595 | 667 | 773 | 864 | 22 |
Total Common Equity | 555 | 641 | 710 | 548 | -50 |
Shares Outstanding | 83.40 | 83.20 | 83.10 | 82.60 | NA |
Book Value Per Share | 6.66 | 7.70 | 8.54 | 6.63 | 0.00 |
Fiscal Year End for Atea Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 502 | 541 | 578 | 595 | 608 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 7 | 12 | 8 | 13 |
Total Current Assets | 506 | 549 | 590 | 603 | 621 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 2 |
Total Assets | 510 | 553 | 595 | 608 | 626 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 21 | 4 | 0 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 20 | 19 | 27 | 18 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 27 | 41 | 32 | 19 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 6 | 6 | 6 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 34 | 49 | 40 | 26 | 24 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 776 | 763 | 751 | 739 | 726 |
Retained Earnings | -300 | -259 | -196 | -157 | -124 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 476 | 504 | 555 | 582 | 602 |
Total Liabilities & Shareholder's Equity | 510 | 553 | 595 | 608 | 626 |
Total Common Equity | 476 | 504 | 555 | 582 | 602 |
Shares Outstanding | 84.20 | 84.20 | 83.40 | 83.40 | 83.40 |
Book Value Per Share | 5.66 | 5.99 | 6.66 | 6.98 | 7.22 |